Heat Biologics, Inc.
Heat Biologics, Inc. (HTBX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
htbx · pe ratio · data through Dec 31, 2021
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Heat Biologics, Inc. (HTBX) measures how much investors pay for each dollar of the company's trailing earnings. HTBX's current PE ratio of N/A is calculated by dividing its stock price of $2.38 by its TTM earnings per share of -$536576.14.
Source: FMP · /ratios-ttm · /analyst-estimates · 2021-12-31
PE Ratio History
2011 – 2021 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Heat Biologics, Inc.You HTBX | $61M | N/A | — | -$536576.14 |
 Achilles Therapeutics plc ACHL | $61M | N/A | — | -$1.74 |
 AlloVir, Inc. ALVR | $49M | N/A | — | -$0.28 |
 MindWalk Holdings Corp. HYFT | $75M | N/A | — | -$0.91 |
 Kronos Bio, Inc. KRON | $54M | N/A | — | -$1.43 |
 Quince Therapeutics, Inc. QNCX | $6M | N/A | — | -$16.76 |
 Reneo Pharmaceuticals, Inc. RPHM | $61M | N/A | — | $0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2021-12-31Latest FY2021 | — | $-1.41 | — | |
2020-12-31 FY2020 | — | $-1.63 | — | |
2019-12-31 FY2019 | — | $-4.21 | — | |
2018-12-31 FY2018 | — | $-6.30 | — | |
2017-12-31 FY2017 | — | $-21.56 | — | |
2016-12-31 FY2016 | — | $-49.40 | — | |
2015-12-31 FY2015 | — | $-174.92 | — | |
2014-12-31 FY2014 | — | $-126.18 | — | |
2013-12-31 FY2013 | — | $-160.61 | — | |
2012-12-31 FY2012 | — | $-90.87 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Heat Biologics, Inc. (HTBX) measures how much investors pay for each dollar of the company's trailing earnings. HTBX's current PE ratio of N/A is calculated by dividing its stock price of $2.38 by its TTM earnings per share of -$536576.14.
Frequently asked questions
HTBX pe ratio · 6 questionsHTBX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.38 and TTM EPS of -$536576.14. Data sourced from Financial Modeling Prep via HTBX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Heat Biologics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09